TEG001 Insert Integrity from Vector Producer Cells until Medicinal Product
Publication date
2020-02-05
Authors
Straetemans, Trudy
Janssen, Anke
Jansen, Koen
Doorn, Ruud
Aarts, Tineke
van Muyden, Anna D D
Simonis, Marieke
Bergboer, Judith
de Witte, Moniek
Sebestyen, Zsolt
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
Straetemans and colleagues characterized αβT cells engineered to express a defined γδT cell receptor (TEG001) used in a first-in-human clinical study, with TLA in combination with NGS and qPCR. They provide a rapid strategy to evaluate the presence, integrity, and persistence of genetic information along the production chain of any GTMP.
Keywords
engineered T cells, gene therapy medicinal product, GTMP, targeted locus amplification, TEG001, TLA, vector copy number, γδT cells, Taverne, Drug Discovery, Genetics, Molecular Medicine, Molecular Biology, Pharmacology, Journal Article
Citation
Straetemans, T, Janssen, A, Jansen, K, Doorn, R, Aarts, T, van Muyden, A D D, Simonis, M, Bergboer, J, de Witte, M, Sebestyen, Z & Kuball, J 2020, 'TEG001 Insert Integrity from Vector Producer Cells until Medicinal Product', Molecular Therapy, vol. 28, no. 2, pp. 561-571. https://doi.org/10.1016/j.ymthe.2019.11.030